$DNTH
Dianthus Therapeutics, Inc. /DE/

2019 Q4 Form 10-Q Financial Statement

#000119312519290577 Filed on November 13, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.920M $6.120M $5.910M
YoY Change 6.86% 15.91% 36.18%
% of Gross Profit
Research & Development $18.71M $16.52M $13.43M
YoY Change 51.01% 44.72% 38.73%
% of Gross Profit
Depreciation & Amortization $480.0K $480.0K $460.0K
YoY Change 33.33% 128.57% 187.5%
% of Gross Profit
Operating Expenses $24.64M $22.64M $19.34M
YoY Change 37.42% 35.58% 37.88%
Operating Profit -$24.64M -$22.64M -$19.34M
YoY Change 37.41% 35.58% 37.88%
Interest Expense $1.400M $1.650M $1.630M
YoY Change 12.0% 139.13% 340.54%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$23.24M -$20.99M -$17.71M
YoY Change 39.33% 31.02% 29.65%
Income Tax
% Of Pretax Income
Net Earnings -$23.24M -$20.99M -$17.71M
YoY Change 39.32% 31.06% 29.63%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$594.5K -$540.7K -$483.1K
COMMON SHARES
Basic Shares Outstanding 38.99M 38.77M 33.65M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $145.7M $160.6M $172.3M
YoY Change 2.17% 0.56% -0.63%
Cash & Equivalents $65.07M $85.51M $33.11M
Short-Term Investments $80.70M $75.10M $139.2M
Other Short-Term Assets $4.100M $4.700M $10.70M
YoY Change 46.43% 46.88% 328.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $149.8M $165.2M $183.0M
YoY Change 3.11% 1.45% 4.03%
LONG-TERM ASSETS
Property, Plant & Equipment $9.891M $10.22M $10.65M
YoY Change -3.14% 25.45% 265.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.800M $1.800M $1.800M
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $11.67M $12.00M $12.43M
YoY Change -2.68% 20.89% 164.88%
TOTAL ASSETS
Total Short-Term Assets $149.8M $165.2M $183.0M
Total Long-Term Assets $11.67M $12.00M $12.43M
Total Assets $161.5M $177.2M $195.4M
YoY Change 2.67% 2.57% 8.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.812M $2.038M $2.349M
YoY Change -19.47% -58.38% 56.91%
Accrued Expenses $11.30M $7.591M $7.591M
YoY Change 63.17% 7.95% 24.28%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $14.12M $9.629M $9.940M
YoY Change 35.47% -19.28% 30.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.200M $6.100M $5.900M
YoY Change 416.67% 454.55% 637.5%
Total Long-Term Liabilities $6.200M $6.100M $5.900M
YoY Change 397.59% 464.81% 641.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.12M $9.629M $9.940M
Total Long-Term Liabilities $6.200M $6.100M $5.900M
Total Liabilities $20.32M $15.70M $15.89M
YoY Change 74.2% 20.72% 89.08%
SHAREHOLDERS EQUITY
Retained Earnings -$179.5M -$156.3M -$135.3M
YoY Change 74.73% 81.6% 93.15%
Common Stock $320.7M $317.7M $314.7M
YoY Change 29.11% 29.24% 29.9%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $141.2M $161.5M $179.6M
YoY Change
Total Liabilities & Shareholders Equity $161.5M $177.2M $195.4M
YoY Change 2.67% 2.57% 8.21%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$23.24M -$20.99M -$17.71M
YoY Change 39.32% 31.06% 29.63%
Depreciation, Depletion And Amortization $480.0K $480.0K $460.0K
YoY Change 33.33% 128.57% 187.5%
Cash From Operating Activities -$15.62M -$11.51M -$15.03M
YoY Change 23.67% 9.1% 64.98%
INVESTING ACTIVITIES
Capital Expenditures -$150.0K -$530.0K -$1.130M
YoY Change -96.55% -78.54% 63.77%
Acquisitions
YoY Change
Other Investing Activities -$5.570M $64.34M -$42.70M
YoY Change -93.37% -427100.0%
Cash From Investing Activities -$5.730M $63.81M -$43.82M
YoY Change -93.52% -2672.98% 6440.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $60.30M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 920.0K 90.00K 60.73M
YoY Change -295.74% -112.33% -57.69%
NET CHANGE
Cash From Operating Activities -15.62M -11.51M -15.03M
Cash From Investing Activities -5.730M 63.81M -43.82M
Cash From Financing Activities 920.0K 90.00K 60.73M
Net Change In Cash -20.43M 52.39M 1.880M
YoY Change -79.87% -480.74% -98.59%
FREE CASH FLOW
Cash From Operating Activities -$15.62M -$11.51M -$15.03M
Capital Expenditures -$150.0K -$530.0K -$1.130M
Free Cash Flow -$15.47M -$10.98M -$13.90M
YoY Change 86.84% 35.89% 65.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1780000
CY2018Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1780000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10223000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10212000
CY2019Q3 us-gaap Assets
Assets
177233000
CY2018Q4 us-gaap Assets
Assets
157313000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
85507000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
58345000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
157313000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
75063000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
84225000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4660000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2751000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
165230000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
145321000
CY2019Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6075000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1246000
CY2019Q3 us-gaap Liabilities
Liabilities
15704000
CY2018Q4 us-gaap Liabilities
Liabilities
11665000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
177233000
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2038000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3492000
CY2019Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7591000
CY2018Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6927000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9629000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10419000
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
39000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
33000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
317665000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
248349000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-156258000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102726000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
161529000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16524000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11418000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40494000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28950000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6120000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5284000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17838000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13083000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
22644000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
16702000
us-gaap Operating Expenses
OperatingExpenses
58332000
us-gaap Operating Expenses
OperatingExpenses
42033000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-56000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
91000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21046000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16015000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53441000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40836000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22644000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16702000
us-gaap Operating Income Loss
OperatingIncomeLoss
-58332000
us-gaap Operating Income Loss
OperatingIncomeLoss
-42033000
CY2019Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1654000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7939000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8152000
CY2018Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
687000
us-gaap Interest And Other Income
InterestAndOtherIncome
4800000
us-gaap Interest And Other Income
InterestAndOtherIncome
1197000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-56000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
91000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
179556000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
257000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
172217000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
145648000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1107000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-42118000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
29000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2762000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3676000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
159784000
us-gaap Profit Loss
ProfitLoss
-53532000
us-gaap Profit Loss
ProfitLoss
-40836000
us-gaap Share Based Compensation
ShareBasedCompensation
7939000
us-gaap Share Based Compensation
ShareBasedCompensation
8152000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1358000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
516000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
909000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1909000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2085000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-629000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2104000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1377000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1740000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-4829000
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-1080000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-41476000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29262000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2907000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3321000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
94176000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
104338000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7255000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3309000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
598000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2618000
mgta Payments Of Preferred Stock Issuance Costs
PaymentsOfPreferredStockIssuanceCosts
88000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1107000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
61383000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
142623000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27162000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
110052000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60125000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51567000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87287000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
161619000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3467000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-57500000
CY2019Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
74980000
CY2019Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
83000
CY2019Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
75063000
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
84233000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
84225000
CY2019Q3 mgta Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
3894000
CY2018Q4 mgta Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2619000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
446000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
787000
CY2019Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
601000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2428000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2526000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
60276000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
88000
mgta Temporary Equity Conversion Of Redeemable Convertible Preferred Stock To Common Stock Value
TemporaryEquityConversionOfRedeemableConvertiblePreferredStockToCommonStockValue
144739000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
89906000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-67000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60874000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
93000000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
52300000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
144739000
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
88000
CY2019Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60300000
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7591000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6927000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
71000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
222000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
211000
CY2018Q4 mgta Accrued Property Plant And Equipment
AccruedPropertyPlantAndEquipment
713000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2762000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3676000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7939000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8152000
CY2019Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
18000000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-20990000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-16015000
us-gaap Net Income Loss
NetIncomeLoss
-53532000
us-gaap Net Income Loss
NetIncomeLoss
-40836000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20990000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16015000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-53532000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40924000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38824209
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32997346
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36322804
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13396856
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.05
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
1405000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
5782000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
6072000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
6375000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
6734000
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
32000000
CY2019Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1800000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
4600000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2900000
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Trading Symbol
TradingSymbol
MGTA
dei Entity Registrant Name
EntityRegistrantName
Magenta Therapeutics, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001690585
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38989517
dei Security12b Title
Security12bTitle
Common Stock
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39370576
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34327554
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33305033
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
123000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
29000
mgta Offering Costs Included In Accounts Payable And Accrued Expenses
OfferingCostsIncludedInAccountsPayableAndAccruedExpenses
476000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2015-06-30
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
23375405
CY2019Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
In May 2018, the Company entered into a sublease for up to approximately 69,000 square feet of office and laboratory space in Cambridge, Massachusetts. The sublease was amended effective March 2019 to increase the lease payments over the lease term and to increase the sublandlord-funded tenant improvements. The sublease is subject and subordinate to a prime lease between the sublandlord and the prime landlord. The term of the sublease commenced in June 2018 and expires in February 2028. The sublandlord has the right to terminate the sublease after five years.
mgta Sublease Commencement Period
SubleaseCommencementPeriod
2018-06
mgta Sublease Expiration Period
SubleaseExpirationPeriod
2028-02
CY2018Q2 mgta Sublease Termination Period
SubleaseTerminationPeriod
P5Y
CY2019Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
58368000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5330904
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4783669
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38942719
CY2019Q3 us-gaap Revenues
Revenues
0
CY2018Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
0
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE

Files In Submission

Name View Source Status
0001193125-19-290577-index-headers.html Edgar Link pending
0001193125-19-290577-index.html Edgar Link pending
0001193125-19-290577.txt Edgar Link pending
0001193125-19-290577-xbrl.zip Edgar Link pending
d814077d10q.htm Edgar Link pending
d814077dex101.htm Edgar Link pending
d814077dex102.htm Edgar Link pending
d814077dex311.htm Edgar Link pending
d814077dex312.htm Edgar Link pending
d814077dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mgta-20190930.xml Edgar Link completed
mgta-20190930.xsd Edgar Link pending
mgta-20190930_cal.xml Edgar Link unprocessable
mgta-20190930_def.xml Edgar Link unprocessable
mgta-20190930_lab.xml Edgar Link unprocessable
mgta-20190930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending